

# Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX

Crystal Traylor,<sup>1</sup> Vladimir Tesar,<sup>2</sup> Hernán Trimarchi,<sup>3</sup> James Tumlin,<sup>4</sup> Laura Kooienga,<sup>5</sup> Radko Komers,<sup>1</sup> Julia Inrig,<sup>1</sup> Edward Murphy,<sup>1</sup> Eva Rodríguez García<sup>6</sup>

<sup>1</sup>Travere Therapeutics, Inc., San Diego, CA, USA; <sup>2</sup>General University Hospital in Prague, Prague, Czech Republic; <sup>3</sup>British Hospital of Buenos Aires, Buenos Aires, Argentina; <sup>4</sup>NephroNet Clinical Trials Consortium & Emory University School of Medicine, Atlanta, GA, USA; <sup>5</sup>Colorado Kidney Care, Denver, CO, USA; <sup>6</sup>Hospital del Mar, Barcelona, Spain

## INTRODUCTION

- FSGS is associated with a substantial risk of kidney failure, with 40% to 60% of patients progressing to kidney failure or death within 10 to 20 years of diagnosis<sup>1,2</sup>
- There are no approved therapies for FSGS, highlighting an unmet need for safe and effective treatments<sup>3</sup>
- In large-scale analyses of observational data, proteinuria was identified as a biologically plausible and clinically meaningful endpoint, with lower proteinuria strongly associated with reduced kidney failure risk<sup>4</sup>
- Sparsentan is a non-immunosuppressive dual endothelin angiotensin receptor antagonist (DEARA)<sup>5,6</sup> that led to rapid and sustained proteinuria reductions in patients with FSGS in the phase 3 DUPLEX trial<sup>7</sup>

## OBJECTIVE


- Expanding on earlier findings from this trial, we investigated the impact of sparsentan vs irbesartan on low proteinuria targets and the effect of achieving CR of proteinuria or the FSGS partial remission endpoint on progression to kidney failure in DUPLEX

## METHODS

### DUPLEX Study Design

- DUPLEX (NCT03493685) is a phase 3, randomized, double-blind trial investigating the safety and efficacy of sparsentan vs active control, maximum labeled dose irbesartan, in adults and children (aged ≥8 years) with FSGS

Figure 1. DUPLEX Study Design



- Analyses investigated the impact of sparsentan vs irbesartan on the proportion of patients achieving CR of proteinuria, the FSGS partial remission endpoint, and UPCR of <0.5 g/g, <1.0 g/g, and <1.5 g/g at any time during the 108-week double-blind treatment period
- Pooled analyses using data from both treatment arms evaluated rates of progression to kidney failure at any time during the double-blind period in patients who achieved vs did not achieve CR of proteinuria or the FSGS partial remission endpoint

## RESULTS

### Patient Population

- A total of 371 patients were randomized to receive sparsentan or irbesartan in DUPLEX

Table 1. Patient Demographics and Baseline Characteristics


	Sparsentan n=184	Irbesartan n=187	All patients N=371
Age, mean (SD), years	41.7 (16.5)	41.5 (17.3)	41.6 (16.9)
<18 years, n (%)	16 (8.7)	19 (10.2)	35 (9.4)
Male sex, n (%)	101 (55)	99 (53)	200 (54)
eGFR, mean (SD), mL/min/1.73 m²	63.3 (28.6)	64.1 (31.7)	63.7 (30.1)
UPCR, g/g*			
Median (interquartile range)	3.1 (2.3-4.5)	3.0 (2.1-4.7)	3.0 (2.2-4.6)
Blood pressure, mean (SD) systolic/diastolic, mm Hg	133.1 (14.8)/ 85.5 (10.6)	130.9 (14.6)/ 82.4 (10.1)	-
FSGS-associated genetic variants, n (%)			
Variants in podocyte structure/function proteins	13 (7)	18 (10)	31 (8)
COL4A3-5 variants	11 (6)	14 (7)	25 (7)
High-risk APOL1 variants	9 (5)	5 (3)	14 (4)
Prior RASi use (stopped before washout), n (%)	152 (83)	143 (76)	295 (80)
Baseline use of immunosuppressive agents, n (%)	50 (27)	46 (25)	96 (26)
Baseline use of diuretics, n (%)	68 (37)	73 (39)	141 (38)

\*UPCR was calculated as the geometric mean of 2 to 3 first morning void samples collected within 5 days before each visit.

### Proteinuria

- Sparsentan demonstrated superior and consistent proteinuria reduction across low proteinuria thresholds vs maximum labeled dose irbesartan

Figure 1. Patients Achieved Low Proteinuria Thresholds More Often With Sparsentan vs Irbesartan



\*CR of proteinuria was defined as UPCR <0.3 g/g. †The FSGS partial remission endpoint was defined as UPCR ≤1.5 g/g and >40% reduction from baseline.

### ABBREVIATIONS

ALT, alanine aminotransferase; APOL1, apolipoprotein L1; AST, aspartate aminotransferase; CI, confidence interval; COL4A3-5, collagen type IV alpha 3, alpha 4, and alpha 5 chain; CR, complete remission; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; NE, not estimable; RASi, renin-angiotensin system inhibitor; RR, relative risk; SD, standard deviation; SOC, standard of care; TEAE, treatment-emergent adverse event; ULN, upper limit of normal; UPCR, urine protein-to-creatinine ratio.

## CONCLUSIONS


- Dual endothelin angiotensin receptor blockade with sparsentan led to clinically meaningful low proteinuria thresholds, including CR of proteinuria or the FSGS partial remission endpoint, being achieved earlier and more often in patients with FSGS than did angiotensin receptor blockade alone with irbesartan
- Consistent with recently reported results from PARASOL,<sup>4</sup> patients who reached CR of proteinuria or the FSGS partial remission endpoint showed markedly reduced risk of progression to kidney failure
- Sparsentan was generally well tolerated over 108 weeks of treatment, with a safety profile comparable to that of irbesartan

## KEY TAKEAWAY

Patients with FSGS achieved proteinuria reductions, including CR of proteinuria or the FSGS partial remission endpoint, earlier and more often with sparsentan vs irbesartan, and those who reached these targets had a lower risk of kidney failure, supporting the nephroprotective benefit of sparsentan in FSGS


- Patients reached CR of proteinuria and the FSGS partial remission endpoint earlier with sparsentan vs maximum labeled dose irbesartan
  - Similar results were observed for UPCR of <0.5 g/g, <1.0 g/g, and <1.5 g/g, with patients reaching all thresholds earlier with sparsentan vs irbesartan ( $P \leq .0001$  for difference)

Figure 2. Probability of Achieving CR of Proteinuria\*



\*CR of proteinuria was defined as UPCR of <0.3 g/g. †P value is generated from a stratified Cox proportional hazards model with treatment and baseline log (UPCR) as covariates, stratified by randomization stratification factors.

Figure 3. Probability of Achieving the FSGS Partial Remission Endpoint\*



\*The FSGS partial remission endpoint was defined as UPCR of ≤1.5 g/g and >40% reduction from baseline. †P value is generated from a stratified Cox proportional hazards model with treatment and baseline log (UPCR) as covariates, stratified by randomization stratification factors.

### DISCLOSURES

CT, BK, JT, and EM are employees and may be shareholders of Travere Therapeutics, Inc. VT reports consulting fees and/or honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Calixtas Therapeutics, GSK, Eli Lilly, Novartis, Otsuka Pharmaceuticals, Travere Therapeutics, Inc., and Vera Therapeutics; and clinical trial steering committee membership for Calixtas Therapeutics, Novartis, Otsuka Pharmaceuticals, Travere Therapeutics, Inc., and Vera Therapeutics. WT reports grants and/or consulting fees from AstraZeneca, Bayer, Biocryl Pharmaceuticals, Bogen Inc., Calixtas Therapeutics, Chirok Therapeutics, Dimen, George Clinical, Novartis, Omers, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, Timberline Therapeutics, Travere Therapeutics, Inc., and Vera Therapeutics; honoraria and/or travel support from AstraZeneca, Biocryl Pharmaceuticals, Calixtas Therapeutics, Chirok Therapeutics, George Clinical, Novartis, and Travere Therapeutics, Inc.; and data safety monitoring or advisory board participation for AstraZeneca, Biocryl Pharmaceuticals, Calixtas Therapeutics, Chirok Therapeutics, Novartis, and Travere Therapeutics, Inc. JT reports grants and/or consulting fees from Akebia Therapeutics, Alexion Pharmaceuticals, argenx, AstraZeneca, Aumia Pharmaceuticals Inc., Bogen Inc., Dimeriv Limited, Humacyte Global Inc., La Jolla Pharmaceutical Company, Halocort Pharmaceuticals, Hedronix Inc., Otsuka Pharmaceuticals, Palatin Technologies, Pfizer, Travere Therapeutics, Inc., Vera Therapeutics, and Vertex Pharmaceuticals; and advisory board or speaker bureau participation for Alexion Pharmaceuticals, Vera Therapeutics, and Vertex Pharmaceuticals. BK is principal investigator for studies sponsored by Akebia Therapeutics, Alexion Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Chirok Therapeutics, CSL Behring, Galderma, Mineralys Therapeutics, Inc., Novartis, Omers, Otsuka Pharmaceuticals, Reata Pharmaceuticals, Travere Therapeutics, Inc., Vera Therapeutics, Visterra, and Walden Biosciences; and reports advisory board participation for Novartis and Otsuka Pharmaceuticals. ERG reports non-financial support from GSK, Teunim, Otsuka, and Vifor; payments for scientific sessions from Teunim, GSK, and Otsuka; advisory board participation for Alexion and Otsuka; and basic research grants from Travere Therapeutics, Inc.




To obtain a PDF of this poster, please scan the Quick Response (QR) code. No personal information is stored.

### Kidney Failure Risk

- Irrespective of treatment arm, patients who achieved CR of proteinuria or the FSGS partial remission endpoint were less likely to reach kidney failure vs those who did not

Figure 4. Probability of Reaching Kidney Failure\*



\*Results from post hoc analyses using pooled data irrespective of treatment arm. CR of proteinuria was defined as UPCR of <0.3 g/g. The FSGS partial remission endpoint was defined as UPCR of ≤1.5 g/g and >40% reduction from baseline. †Kidney failure was defined as sustained eGFR of <15 mL/min/1.73 m² or kidney replacement therapy.

### Safety

- Sparsentan was well tolerated, with a safety profile comparable to that of irbesartan
  - The most common TEAEs (≥15% in either group) included COVID-19, hyperkalemia, peripheral edema, and hypotension

Table 2. Adverse Events

Patients with TEAEs, n (%)	Sparsentan n=184	Irbesartan n=187	All patients N=371
Any TEAEs	172 (93)	174 (93)	346 (93)
Serious TEAEs	68 (37)	82 (44)	150 (40)
TEAEs of interest			
Fluid retention-associated TEAEs	47 (26)	56 (30)	103 (28)
Hyperkalemia-associated TEAEs	37 (20)	21 (11)	58 (16)
Hypotension	33 (18)	21 (11)	54 (15)
Anemia	24 (13)	10 (5)	34 (9)
Dizziness	23 (13)	21 (11)	44 (12)
Acute kidney injury	8 (4)	13 (7)	21 (6)
ALT or AST >3 × ULN	5 (3)	4 (2)	9 (2)
Heart failure	0	0	0

### ACKNOWLEDGMENTS

This study was funded by Travere Therapeutics, Inc. Medical writing support was provided under the direction of the authors by Taryn Raigh, PhD, and CJ Henley-Smith, PhD, of Nucleus Global, an Inizio company, in accordance with Good Publication Practice guidelines, and was funded by Travere Therapeutics, Inc. The authors thank all the patients, families, and investigators who made this study possible.

